Healthcare, Pharma & Life Sciences

NEW YORK – November 04, 2026 -- Itemize, an AI Finance Operations provider, has appointed Doug Airulla, a healthcare payments veteran with more than 25 years of experience, as Product Manager for Healthcare Operations & Revenue Cycle.

Airulla will lead development of Itemize's healthcare solutions for providers, payers, Revenue Cycle Management (RCM) organizations and healthcare business process outsourcing companies. He will own the product roadmap and its commercialization.

Airulla brings Wells Fargo and J.P. Morgan treasury experience

Airulla joins from Wells Fargo, where he was Executive Director and Senior Product Solutions Specialist. There he advised healthcare organizations on revenue cycle and treasury management. He has helped close more than $60 million in revenue over his career.

Plano, Texas – November 04, 2026 -- CorroHealth CEO Pat Leonard has been named to CEO Magazine's 2026 Executive of the Year Awards, after a nomination and evaluation process, the revenue cycle technology company said.

The magazine cited Leonard's strategic vision and operational discipline in building a foundation for accelerated growth. The awards recognize senior executives who drive business growth and transformation, champion innovation, build high-performing teams and navigate complex markets.

Leonard has led CorroHealth's operational transformation since 2020

Under Leonard, CorroHealth has combined clinician-led expertise with proprietary AI-driven technology. The company says the combination has made it a preferred partner in healthcare technology and revenue cycle management.

New York – November 04, 2026 -- Morning email sends delivered a 13% higher weighted composite engagement score than afternoon sends in a biopharma campaign, contradicting existing predictive models, according to GrowthLoop and EVERSANA, which are expanding their Composable AI Decisioning solution into biopharmaceutical marketing.

The solution builds on GrowthLoop's composable customer data platform (CDP) and AI Studio. It uses continuous experimentation to identify which marketing actions lift healthcare professional (HCP) engagement, then feeds those findings into AI decisioning for subsequent interactions.

Austin – November 04, 2026 -- Genprex, Inc. (NASDAQ: GNPX) reported that low TROP2 expression was consistently associated with primary resistance to its lead gene therapy Reqorsa (quaratusugene ozeplasmid) across multiple preclinical non-small cell lung cancer (NSCLC) models. The company says the finding could guide patient selection in future trials.

About half of tested NSCLC models showed primary resistance

Approximately 50% of 10 NSCLC cell lines and 50% of 12 patient-derived organoid models showed primary resistance to TUSC2 gene delivery. Protein-expression analyses identified low TROP2 expression as a marker associated with that resistance.

Patient biopsies from a TUSC2 trial back the association

Analysis of pretreatment tumor biopsies from patients enrolled in a TUSC2 gene therapy clinical trial supported the link between TROP2 expression and treatment response. The company did not disclose patient numbers or effect sizes.

Newton, Mass. – November 04, 2026 -- Karyopharm Therapeutics (Nasdaq: KPTI) will present Week 48 data from its Phase 3 SENTRY trial and early monotherapy data from its Phase 2 SENTRY-2 trial in two oral sessions at ASH 2026, giving selinexor two oral slots in myelofibrosis. A third abstract, from the STOMP trial in multiple myeloma, was selected for a poster.

SENTRY Week 48 data go on stage December 13

The SENTRY presentation (publication number 526) is scheduled for December 13, 2026, from 10:15 a.m. to 10:30 a.m. CT. It will cover updated results for selinexor plus ruxolitinib in JAK inhibitor-naïve myelofibrosis. Chief Medical Officer Reshma Rangwala said the data show ongoing benefit through week 48.

BOULDER, Colo. – November 04, 2026 -- Edgewise Therapeutics (Nasdaq: EWTX) reported third-quarter 2026 net income of $1,166.2 million, or $9.65 per diluted share, driven by a $1.348 billion gain on the sale of its sevasemten program and muscular dystrophy business to Servier. In the same period of 2025, the company posted a net loss of $40.7 million, or $0.39 per share.

Servier sale delivers $1.396 billion in upfront cash

The transaction closed in July 2026. Edgewise received $1.396 billion in upfront cash at closing. The reported gain includes consideration recognized at closing, among it amounts tied to the general indemnification arrangement. It is stated net of the carrying value of transferred assets, transaction costs and consideration allocated to transition services. Income tax expense associated with the transaction partly offset the gain in net income.

Vancouver – November 04, 2026 -- IM Cannabis Corp. (Nasdaq: IMCC) has closed a US$1,200,000 convertible note financing with an existing institutional investor, issuing the note at an original issuance discount of 15% under a purchase agreement dated November 4, 2026.

Note carries 4% interest and a 28-month maturity

The note bears interest of 4% per annum, rising to 14% if an event of default occurs and continues. It matures 28 months after issuance and is repayable in 10 equal monthly instalments starting after the 18th month. The investor may convert all or part of the outstanding balance into common shares on one or more occasions.

Madison, Wisconsin – November 04, 2026 -- Accuray Incorporated (NASDAQ: ARAY) will cut its outstanding common shares from about 120.2 million to about 3.0 million through a 1-for-40 reverse stock split effective at 12:02 a.m. Eastern Time on November 9, 2026. The move is intended to lift the per-share price and restore compliance with the minimum bid price requirement for The Nasdaq Capital Market.

Accuray begins split-adjusted trading on Nasdaq on November 9 under a new CUSIP

The company's board approved the split. Shares are expected to trade on a split-adjusted basis at the Nasdaq open on November 9 under the existing symbol "ARAY" and a new CUSIP number, 004397 303. Every 40 issued and outstanding shares will automatically combine into one share.

PHILADELPHIA – – November 04, 2026 -- Verismo Therapeutics' CD19-targeted KIR-CAR T therapy SynKIR-310 produced an 80% objective response rate (4 of 5 evaluable patients) in relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL), with no cytokine release syndrome (CRS) or neurotoxicity (ICANS) of any grade. The data come from the first two dose cohorts of the Phase 1 CELESTIAL-301 trial (NCT06544265). The company will present updated results as an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting.

SynKIR-310 delivers 60% complete response rate and no dose-limiting toxicities in early cohorts

Across dose cohorts 1 and 2, the complete response rate was 60%. Median duration of response in complete responders has not been reached, and one patient remained in complete response at the 12-month assessment.

CRANFORD, N.J. – November 05, 2026 -- Citius Oncology (Nasdaq: CTOR) reported that 13 of 41 heavily pretreated cutaneous T-cell lymphoma (CTCL) patients with significant itch (32%; 95% CI, 18.1–48.1) achieved a clinically meaningful itch reduction on LYMPHIR (denileukin diftitox-cxdl) in the pivotal Study 302. The health-related quality of life (HRQoL) data were presented orally by Christiane Querfeld, MD, PhD, of City of Hope at the EORTC-CLTG 2026 Annual Meeting in Berlin, held October 8–10, 2026.

Responders show Skindex-29 improvement of up to 13.69 points

Among 25 responders in the primary analysis set (Stage I–III, n=69), the mean change from baseline in Skindex-29 Total Score ranged from −5.38 to −13.69 points across assessments. Lower scores indicate better quality of life. Non-responders showed slightly positive to near-zero changes.